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Prevention of Maternal Rho (D) Sensitization 
llist2£Y-
Erythroblastosis fetalis is an ancient disease; the hydropic form 
was probably known to Hippocrates. However, it was not until 1932 that 
three forms - hydrops, icterus gravis, and anemia of the newborn - were 
shown to be the same disease. 26 Landsteiner and Wiener 47 discovered 
the RH antigen in 1940. The antigen was first found on the red cell of 
the rhesus monkey, and hence its name, Rh factor. In 1941, Levine 50 
recognized the relationship between erythroblastosis fetalis and atypical 
agglutinins in the mothers I serum which were identical to the anti-·Rh 
agglutinin of Landsteiner. Several of Levine's patients had transfusion 
reactions after delivery when they received blood from their husbands. 
He suggested that the infant inherited something from the father to which 
the mother had antibody. The antibody then crossed the placenta where 
it caused the damage typical of erythroblastosis fetalis. This theory 
is the basis of Rh isoimmunization. 
Levine 48 later added fetal-maternal ABO blood group incompatibility 
to the causes of erythroblastosis fetalis and confirmed Landsteiner's 
finding that Rh factor is inherited as a mendelian dominant gene. 
The neonatal mortality of the disease was greatly reduced in 1947 
when Diamond 23 proposed exchange transfusions. Liley 51 introduced the 
daring concept of intra-uterine transfusions as the next step in therapy 
in 1964. 
Two groups of investigators, working independently and using dif-
ferent approaches, found a method for preventing erythroblastosis 
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fetalis early in the 1960's. Finn and Clark 29 in Liverpool, England 
were impressed with Levine's finding that ABO incompatibility between the 
mother and the fetus seemed to prevent isoimmunization of the mother 
to the Rh factor. 49 This was believed to be because the ABO agglut-
inins cleared the fetal red cells from the mother's blood before Rh 
isoimmunization could take place. They reasoned, "It seemed that cir-
culating Rh positive fetal cells might be similarly eliminated by the 
administration of anti-D (anti-Rho)' thus preventing sensitization of 
the mother. n 'I'hey were able to prove this by injecting Rh positive 
blood and serum from Rh sensitized women into Rh negative male volunteers. 
At the same time, Freda, German, and Pollack 33 in the United States 
were basing their work on the classical findings of Theobald Smith. 74 
While working with Diphtheria toxin-antitoxin mixtures in 1909, Smith 
showed that !' ••• an excess of antitoxin reduces the possibility of 
producing an active immunity, and may extinguish it altogether. ll Freda's 
group was able to prevent Rh-negative isoimmunization in male volunteers 
with anti-Rh gamma-globin. These results suggested an effective method 
of preventing hemolytic disease of the newborn caused by Rh isoim-
o 
munization. 
Research in the past decade has followed three principal directions. 
Kleihauer 44 reported a simple and sensitive method for identifying fetal 
red cells in adult blood in 1957. Many workers have used this technique 
to determine the frequency, timing and volume of transplacental fetal-
maternal hemorrhage. 17,20,54,84 Other investigators have clarified 
,-
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the maternal immune response and attempted to find how it is suppressed 
by passive gamma-globin. 46,72,77,80,87 The third approach has been 
clinical trials with passively administered gamma-globin in Rho negative 
mothers who have delivered Rho positive infants. Several large series 
have reported this treatment to be nearly one-hundred percent effective 
in preventing Rh isoimmunization. 28,40,66 
Diamond 24 recently commented on the unique history of hemolytic 
disease of the newborn due to the Rh factor: llRarely has it been our 
good fortune to have a disease recognized, its cause clearly determined, 
its treatment successfully developed to a great extent, and then its 
prevention found, all in one generation. 1i 
Incidence ------
The Rho antigen (D) occurs in about 85% of the Caucasian population. 
It is present in only 70% of the Basques, 75% of the Negros, and is rarely 
absent in Chinese, Japanese, and American Indians. 49 About 12% of fam-
ilies are at risk because of Rh incompatibility, but sensitization takes 
place in only about 12% of these or 1.4% overall. There are about 
400,000 risk pregnancies per year in the U.S. and 20,000 to 40,000 new 
sensitizations if no preventive treatment is used. 35 These estimates 
agree with Smith 1 s series of 12,297 pregnancies in which 173 women or 
1.4% became immunized to Rho. 73 
Hemolytic disease of the newborn occurs in about 1.8% of all 
deliveries. This is caused by ABO incompatibility in 1.2%, Rho incom-
patibility in 0.6%, and rarely by other blood factors. 61 The perinatal 
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mortality in Rh affected infants has been reported as 36% when the 
antibody appeared before the fifth month and 15% when it first appeared 
after the sixth month. 52 The stillbirth rate in Rh hemolJ~ic disease 
has remained about 15% resulting in about 5,000 stillbirths each year 
in the United States. 26,30 
TransElacental hemorrha~~. 
The first event in Rh hemolytic disease is the leakage of fetal 
red cells into the maternal circulation. This leakage is thought to 
take place in the placenta, through breaks in fetal capillaries in 
the chorionic villi. The fetal cells then enter the intervillous 
space and the mother's general circulation. Research on transplacental 
hemorrhage (TPH) has contributed heavily to the development of a method 
of preventing maternal isoimmunization to the Rho antigen. 
Most workers use the Kleihauer 44 technique to detect TPH. This 
is an acid elution method that destroyes adult red cells. The preserved 
fetal red cells then show up against a background of adult ghost cells. 
Fetal hemorrhages as small as 0.1 mI. can be identified in the mat-
ernal blood by this technique. 88 This method is also used to 
quanitate TPH; five cells per 50 low power microscope fields is equal 
to 0.25 milliliters of fetal blood. 38 Although there is good agreement 
with results from immunofluorescent methods, 19 the Kleihauer technique 
has several possible errors that makes comparison of data from dif-
ferent laboratories difficult. Fetal cells contain hemoglobin F 
almost exclusively, but adult cells may also contain small amounts of 
hemoglobin F. Which makes them show up with the Kleihauer technique. 
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Woodrow 84 found that hemoglobin F not due to fetal cells occurs in 
6.3% of blood samples from pregnant women, in 2% of those from non-preg-
nant women, and 1.9% of those from a general hospital population. One-
fourth of all slides have some irregularly stained cells and ndefinite 
foetal cellsI' are occasionally seen in non-pregnant women. Woodrow 
suggests that three cells per 50 low power fields or 0.15 ml. be the 
minimum criterium for TPH. 84 
Other factors should be considered when studying TPH data. Fetal 
cells have a normal survival time ot about 80 days in the maternal cir-
culation. 19,20,71)87 Thus, there is an additive effect from frequent 
small hemorrhages as the pregnancy approaches term. Hindemann 41 showed 
that fetal red cells are absorbed from the adult peritoneal cavity and 
sometimes do not appear in the circulation for as long as 13 days after 
they are introduced. He also found that late invasion of the maternal 
blood by fetal red cells occurs in 3% of vaginal deliveries. This pos-
sible transabdominal route could explain maternal sensitization when no 
fetal cells were found immediately post-partum. 
The frequency of TPH cannot be stated simply. Many factors seem 
to influence it, including how often fetal cells are searched for in 
the maternal blood and how generous are the worker's criteria for TPH. 
(See table 1). Cohen 19 believes that small transplacental hemorrhages 
are physiologic. Clayton 17 found that fetal cells are present at some 
time during pregnancy in 72% of pregnant patients when their blood is 
examined at each pre-natal visit. Other factors that alter the frequency 
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The time of the sensitizing dose of fetal cells is an important 
and sometimes controversial point. Fetal red cells are detected in 
the maternal blood as early as the 14th week of gestation and in 12% 
of pregnancies by the 20th week. 17 
McLarey 54 found fetal cells in 54% of his patients between 21 
and 42 weeks of gestation. He found no increase in frequency during the 
third trimester but showed that the volume of TPH increases as term 
nears. Woodrow 84 using stricter criteria, found evidence for TPH only 
during the third trimester. Woodrow 84 and Schneider 71 studying women 
at term, demonstrated TPH in only 12% and 15.6% respectively. 
Several studies have shown the incidence of fetal cells in manternal 
blood postpartum to be about 50%. 9,19,20 Woodrow 84 found TPH greater 
than 0.1, mI. in 19.8% of patients after delivery. In a similar study 
he reported fetal cells post-partum in 23% of patients who had no evidence 
of TPH before delivery. 83 Clark 12 made retrograde injections of 
tagged red cells through the umbilical vein at delivery. He found sig-
nificant TPH in about one-third of his patients. 
The volume of fetal-maternal hemorrhage varies from a trace to a 
reported 250 ml. 53 Most evidence suggests that the larger hemorrhages 
usually occur at term and during delivery. McLarey 54 found that TPH 
greater than 0.5 ml. occurred in 10% of pregnancies at some ~ime before 
delivery. Clayton 17 found the same incidence for TPH greater than 0.1 
ml. during pregnancy. Hemorrhages larger than 0.25 ml. have been 
reported in 9% and 16% of post-partum patients. ).3,83 Recently, massive 
TPH has been described as the cause of newborn anemia and maternal trans-
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fusion reactions. 5,19,53,63 These very large hemorrhages occur in 
about 1% of pregnancies. 19,29 
Fetal maternal ABO incompatibility has a significant effect on 
TPH. Both the incidence and volume of TPH are decreased in ABO incom-
patible pregnancies as compared to compatible pregnancies. 9.13,29,55,87,88 
This difference may be due to rapid clearance of incompatible cells from 
the maternal circulation; however, Cohen 20 showed normal survival of 
ABO incompatible fetal cells in cases of massive TPH. 
Cesarean section, large placentae, manual removal of the placenta. 
and cervical laceration at delivery all are associated with increased 
risk of 'I'PH. 9.55,58,88 Transabdominal amniocentesis does not seem to 
increase TPH if done with ease. 10,85 88 Z ipur sky reported an increased 
incidence in primiparas; however, other workers found no significant 
relationship between TPH and maternal age, parity, previous abortion, 
infarcted placentae, duration of labor, or Apgar of the infant. 9.54 
Finally, fetal-maternal Rh incompatibility does not seem to protect 
against TPH as effectively as ABO incompatibility. 13.54,87 
These data suggest that transplacental hemorrhage, while common 
during pregnancy, is rare before the third trimester. Fetal cells are 
present post-partum in about 50% of women and are present in volumes 
greater than 0.25 ml. in about 10.% 81 
Immunization 
The Rh antigen is much more complicated than first thought. There 
are three pairs of allelomorphic genes and corresponding antigens in 
_Wi 
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the Rh system. These genes are inherited as mendelian dominants and 
recessives which give rise to eight phenotJ~es. 26 (see Table 2). In 
addition, the Rho (D) antigen is made up of several components, some 
of which may be absent in certain individuals. These people, designated 
DU , are Rh positive but make antibody to the complete D antigen. 6 
Grobbelaar 37 believes that, "Many, possibly all, Rho antisera are poly-
valent and contain a spectrum of antibodies of different specificities, 
anti-Rho' anti-R0:1 etc.!' The following discussion will be limited to 
the Rho antigen which is the most antigenic and the only one which 
26,76 
commonly causes hemolytic disease of the newborn. 
Smith 73 screened 12,297 random pregnancies and found that 1.4% 
were immunized to Rho. When only Rh negative women are studied, the rate 
of immunization increases with the volume of fetal cells present after 
delivery. (See Table 3). Several workers agree that volumes of TPH 
smaller than 0.1 ml. cause sensitization of from 2.6 to 4.6%>e:f' Rh neg-
71,83,86 86 6% ative women. Zipursky found that 15. ~ of Rh negative 
mothers were immunized by TPH greater than 0.1 mI. Finn 28 and Wood-
row 83 reported a 20% incidence with TPH greater than 0.25 mI. The risk 
of immunization may reach a limit of 50% as the volume of TPH rises above 
5 to 10 ml. 82 
Although the risk is less, more women may be immunized when no 
fetal cells or only small volumes are demonstrated after delivery. 83,86 
Delayed transabdominal passage of fetal cells into the maternal circulation 
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The time at which maternal sensitization occurs is critical and 
somewhat controversial. Most studies show that maternal antibodies to 
the Rh factor develop within 6 months when none are found at delivery. 28, 
43,66 u d 83,84 . .. 
~oo row feels that most slgnlflcant TPH occurs at or just 
before labor and that immunization begins at that time. Since small TPH 
occurs frequently during pregnancy 17,20.54 and more women are sensitized 
by small volumes of fetal cells 83,86, Zipursky 87 believes that most 
immunization occurs before labor. Chown 11 found anti-Rho antibodies in 
2% of Rh negative primagravidas at the time of delivery. Using sensitive 
tests, Krieger 46 found that twice as many Rh negative mothers were 
immunized during pregnancy as during labor and delivery. Many of these 
would not be detected by direct Coombs tests on cord blood or by routine 
post-partum serologic tests. Bergstrom 3 found Rh antigen on the red 
cells of a 38 day old fetus and suggests immunization by a previous early 
abortion as the cause of antibodies in primagravidas. The higher risk of 
immunizat~on during a second pregnancy suggests that some women with anti-
bodies are not identified. 66 
As would be expected from its effect on TPH, ABO incompatibility 
protects against Rh isoimmunization. The incidence of ABO incompatible 
matings in the general popUlation is 35%, while in those matings which 
result in Rh hemolytic disease of the newborn the incidence is only 13 
t 25 tJ1 49,76 .. o~. It has been shown ln Rh negatlve male volunteers that ABO 
incompatible Rh positive blood is less capable of causing Rh isoimmunization. 
Stern 77 showed that this protective effect is not due to maternal anti-A 
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or anti-B globulin blocking the Rh antigen sites on the fetal cells. 
He felt that the theory of clonal competition for antibody best explained 
this protection: "The basic concept of this theory presupposes that 
presence of clones of antibody-forming cells, each of which produces a 
specific globulin which is identical with an antibody for a specific 
antigen. Exposure to the antigen results in proliferation of the corres-
ponding clone which then synthesizes large amounts of this globulin 
and thus brings about appearance of circulating antibody. The theory 
explains differences between responses to primary and secondary exposure 
to the antigen.!! If, for instance, the Rh negative Type 0 mother has a 
large clone producing anti-A globulin when exposed to fetal cells with 
both A and Rho antigens ..• , the anti-A clone will take up most of the 
fetal cells. This would allow little chance for the potential anti-
Rho close to be stimulated. 77 
Hemolyzed cells are less antigenic than intact cells. 65,71 
Pollack 65 believes that complement fixing antibody of the ABO system 
hemolyzes fetal cells and they are cleared by the liver and kidney before 
Rh immunization can occur. Mollison 57 suggests that the ABO incompat-
ible fetal cells are taken up by the macrophages in the liver which is an 
unfavorable site for antibody formation. 
iihatever the mechanism, ABO incompatible fetal cells are not 
found as often in the maternal circulation and are not as capable of 
Rho isoimmunization as are compatible cells. However, this protection 
is not complete. 
Other factors seem to influence the incidence of Rho immunization. 
-
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79 Taylor found that the Rh type of the grandmother is significant in 
Rh hemolytic disease. An Rh negative women with an Rh positive mother 
was more likely to have an affected infant by the third pregnancy than 
a women with an Rh negative mother. It is possible that these women 
were sinsitized in-utero by their mothers. 
As expected, there is an increased risk of immunization with com-
plicated deliveries, probably a function of increased TPH. 59 
There is also a variable individual response to Rho antigen in 
all studies. Not all women are immunized even with very large TPH. 
Although the rate of immunization of volunteers increases with repeated 
exposure and large amounts of antigen, 71 some Rh negative women do not 
produce antibodies even after many Rh positive pregnancies. Taylor 79 
found that 88% of the women who produced antipodies, did so by three 
Rh positive, ABO compatible pregnancies. Woodrow 81 believes that preg-
nant women in general may be less susceptible to antigen stimulation. 
The maternal immune system usually responds to the Rho antigen on 
the surface of fetal red cells with antibody production. Both macro-
phages and lymphoid tissue are involved in this response. 65 The mother 
makes two types of antibody to the Rho antigen. The first to appear is 
a macroglobin, Igm, which has a molecular weight of 1,000,000, a sed-
imentation constant of 195, and is most active in a saline medium. This 
antibody is present in the serum for about one week then begins to 
decrease as the second type of antibody increases. 69 This antibody, 
IgG, has a molecular weight of 160,000, a sedimentation constant of 75, 
and is most active in an albumin medium. It has been suggested that IgG 
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72 
is responsible for the end of IgM production. The immune response 
will be discussed in greater detail below. 
The placenta is selective in allowing antibody to cross into the 
fetal circulation. The IgM macroglobins cannot cross while the IgG 
antibodies are actively transported. The transfer occurs directly 
across the chorionic villi into the fetal circulation rather than 
indirectly via the amnionic fluid. All fetal antibody is acquired from 
the mother. The fetal gamma globin level remains low until 4 months of 
pregnancy then rises to the maternal level at 9 months and may slightly 
exceed it at term. After birth, the infant begins to produce his own 
antibody as the maternal antibody disappears. The child's antibody 
level does not reach adult levels again until about two years of age. 30 
(See fig. 1). In the fetal circulation the anti-Rho antibody destroys::: 
fetal red cells and produces the changes characteristic of erythro-
blastosis fetalis. 
The mother is only rarelt,-affected by Rho isoimmunization. An 
erythroblastotic maternal syndrome consisting of rapid fluid retention 
without hypertension or proteinuria has been described in mothers with 
severely affected fetuses. All symptoms and signs disappear after 
fetal death or delivery but increase in severity with the next pregnancy. 75 
Rarely, large TPH causes transfusion reactions in Rh immunized mother. 63 
-13-
Figure 1 
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Prevention of Immunization 
Since Levine described the cause of erythroblastosis fetalis, 
interest has turned toward finding a way to prevent the disease. 
Several workers have looked for ways to stop the leakage of fetal 
cells across the placenta. Doolittle 25 reduced the immunization rate 
of Rh negative mothers with a delivery routine that stressed drainage 
and spontaneous delivery of the placenta. Messer 55 used an adren-
ergic drug that increases capillary resistence to injury and 
.-. 
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lessens but does not eliminate 'I'PH. 
The second approach is to limit the maternal immune response. 
Hackel 39 found that components of nucleic acids lower the titer of 
anti-Rh serum in vitro. Sugars and amino sugars produce a similar 
effect. 8,62 The amino sugars are part of the polysaccharide blood 
group antigens and probably combine with antibody to lower titers. 62 
The most successful method of preventing Rh hemolytic disease 
is to suppress maternal antibody production with passive antibody 
administration. Finn 29 and Freda 33 are credited with the discovery 
of this method. In the first experiments Rh negative male volunteers 
received both Rh positive blood and anti-Rh antibody. The antibody 
protected them from isoimmunization to the Rho antigen and produced no 
side effects. 15,16,29,31,33,87 Clinical trials in postpartum Rh 
negative women were then begun and a great deal of data is now avail-
able. (See Table 3). These stUdies show that anti-Rho gamma-globulin 
is almost 100% effective in preventing the appearance of anti-Rho anti-
bodies in the maternal serum after delivery of a Rh positive infant. 28, 
40,66,67,71 
In addition, some of these patients have been followed through 
d Rh 't' 'th t'd f . . t· 28,40,66, a secon pos~ ~ve pregnancy w~ ou ev~ ence 0 ~mmun~za ~on. 
67,71 
In addition, some few patients have been treated after more 
than one Rh positive pregnancy with equally good results after as many 
40 as four treatments. 
A great deal more is known about the mechanism of immune response 
and how it is prevented than was known at the time this treatment was 
-15-
d ' d F' 29 lscovere. lnn assumed that the passive antibody would eliminate 
the fetal cells before the mother was immunized. Studies with Cr51 
tagged Rh negative red cells show that passive anti-Rh antibody does 
increase the clearance of these cells. 29,87 The speed of clearance 
is dose related; the rate of red cell destruction is proportional to 
the square root of the amount of antibody on the cells. 57,71 (See 
figure 2) Delayed clearance of fetal cells is associated with maternal 
immunization in cases of massive TPH protected with small doses of 
passive antibody. 22,42 Clarke 15 suggested that 95% of the incom-
patible cells have to be removed within 24 hours to prevent immunization. 
Most authors now believe that clearance of the fetal cells is 
not as important as antigen competition in the prevention of maternal 
immunization. They base this belief upon what is presently known 
about normal antibody production. 
There are tW0 principal theories of the mechanism of antibody 
production at the present time. The clonal selection theory was 
discussed above in connection with the protective effects of ABO 
incompatibility, 77 This theory does not require the continued presence 
of antigen for antibody production and has been largely supplanted 
by the instructional theory. According to this theory, antigen is 
taken up by macrophages which have the capacity to induce antibody 
formation in the lymphoid tissue. The macrophages produce messenger 
RNA in response to antigen. The messenger RNA carries information 
for IgM production to the lymphoid tissue. 'l'he macrophages are also 
-16-
thought to release RNA-antigen complexes which seek out the already 
committed lymphoid cells. The antigen in the complex selects the 
proper cells and gains entrance for the RNA. These cells then produce 
65 
IgG. This theory requires continued antigen stimulation for anti-
body production and still provides and explanation for the enhanced 
response to a second dose of antigen. The early appearance of IgM 
in the immune response 69 tends to support this theory. 
Figure 2 
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S · k' d 72 1S 1n recently modified this theory to include the affinity of 
circulating antibody as a control mechanism. There is a marked dif-
ference in the affinity of antibody for antigen. This affinity 
increases as the immune response continues. Siskind suggested that 
antibody forming cells have antibody-like molecules on their surface 
which captures antigen. They are then stimulated to produce more 
antibody. Cells with the highest affinity molecules would have the 
best chance to capture antigen and would produce antibody with high 
affinity. 72 This would explain how circulating antibody prevents 
. . 27,72 
hyperimmunization by feedback to the ant1body produc1ng cells. 
These theories help explain some observations about the suppres-
sion of the immune response with passive antibody. The passive anti-
Rho antibody is thought to combine with the Rho antigen and prevent it 
27,35,56,57,65, 
from stimulating lymphoid cells to produce antibody. 
72,80 
The site of this interaction is no~ known for certain but is 
27 
probably extra-circulatory. It is known that Rh antibodies cause 
red cells to be sequestered and broken down in the spleen. 5r,65 
Pollack 65 believes that passive antibody prevents macrophages from 
processing antigen and producing messenger RNA. The antibody may also 
compete with lymphoid cells for RNA-antigen complexes necessary for 
. I G d . 65 cont1nued g pro uct10n. 
Passively administered IgG antibody is more effective in supres-
27,72 
sing active immunization than IgM antibody. Smaller doses of 
high affinity antibody prevent immunization as well as larger doses 
------------------------------,-,-, ---------------------------~.------------------------------
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of low affinity antibody. 56,72 Since IgG is produced late in the 
immune response it; would be expected to have a high affinity for 
antigen and could successfully compete wit;h the lymphoid cells. 
One disturbing result that was found in some trials was sig-
nificant enhancement of immunization when passive antibody was 
15,18,22,65,72 
given. This usually occurred when the doses of gamma 
globin were relatively small. Pollack 65 was able to demonstrate this 
ff t · Rh t' (S F' 3) S· k' , 72 e ec l.rl nega l.ve men. ee l.g. l.S l.na produced similar 
results with very small doses of high affinity antibody. He believes 
that small doses of antibody cause suppression of only the low 
affinity lymphoid cells, allowing the high affinity cells to produce 
relatively more antibody than usual. 
Figure 3 
Enhancement of the Immune Response 
o 1 10 20 40 
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The amount of passive antibody necessary to suppress the maternal 
immune response appears to depend upon the dose of antigen present. 
The passive antibody is measured in micrograms of anti-Rho gamma-
globin. Equally good results are obtained with doses of 200 to 300 
28 /6 
micrograms as with 1000 micrograms. ,0 Most of the treatment 
failures that have been reported are cases of very large fetal-maternal 
22,42,82 
hemorrhage. Hughes-Jones 42 suggests that the absolute num-
ber of unbound antigen sites is the limiting factor in immune suppres-
sion. There are about 12,000 Rho antigen sites on each fetal cell: 
With TPH of 400 milliliters, 10,000 micrograms of gamma-globin would 
be necessary to bind one-half of the antigen sites and suppress 
immunization. Seventy-five micrograms will occupy 10% of the sites on 
one milliliter of fetal cells and prevent immunization. The affinity 
of the antibody for antigen as well as the dosage would affect the 
b f b d "t 42 num er 0 oun s~ es. 
There is some disagreement about when the passive antibody should 
be administered. Suppression is more difficult late in the immune 
response but has been accomplished in animals as long as 40 days 
80 72 
after immunization. Siskind produced late suppression with 
large doses of high affinity antibody. Some authors believe that 
immunization usually occurs during pregnancy rather than after delivery. 
11,46,87 Z" k 87 
~purs Y found that anti-Rho gamma-globin given during 
pregnancy is effective in preventing immunization and does no harm to 
the fetus. The half-life of human gamma-globin is about 30 days and 
would provide prolonged protection if given during pregnancy. 35,87 
, I ~ 
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In most large series the antibody is given within 72 hours of delivery 
28,66 
with excellent results. 
Another important question is which patients should be protected? 
Certa.inly, all Rh negative mothers with Rh positive ABO compatible 
infants should receive gamma-globulin if they are not already immunized. 
'rhe presence of fetal cells in the maternal circulation after delivery 
should not be a requirement for protection. 66,78 Although ABO incom-
49,76 
patibility is protective it is not completely effective. These 
patients with ABO incompatible infants probably should also receive 
66 
anti-Rho antibody. In addition, treatment has been recommended 
after early abortions and any manipulation likely to cause trans-
placental hemorrhage. 3,64 
There is very little risk to this treatment. The danger of 
ser~~ hepatitis has been eliminated by use of gamma-globulin prep-
14 
arations. Clarke found that there is about a 6% incidence of mat-
ernal sensitization to gamma-globulin. This also occurs with blood 
transfusions and rarely causes symptoms. 14 A few local skin reactions 
at the site of injection and fevers lasting 24 hours have also been 
13 
reported. There seems to be no damage to the immune system in gen-
1 .. .. f . . th d 14 era and there ~s no ~ncrease ~n 1n ect10ns ~n ose treate • 
Passive Rh antibody treatment may select against Rh-positive 
fetuses in subsequent pregnancies. Finn 28 found that 50% of the 
treated Rh-negative women had Rh-positive infants with the next preg-
nancy. This is a significant difference from the expected 80% incidence. 
-
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It is not yet clear whether this represents true selection or, 
if so, what are its implications. 
Discussion 
There can be little doubt that anti-Rho gamma-globulin is a safe 
and effective method of suppressing maternal Rho immunization. The 
treatment is still expensive; the price of one standard dose of anti-
Rho gamma-globulin is $50.00 at the University of Nebraska Hospital. 
However, the cost has been lowered and is expected to decrease further. 
rfhe development of this treatment has contributed a great deal 
to the basic understanding of the immune system. The human Rho factor 
is an important research tool because the antigen is normally absent 
in a significant number of people, is naturally introduced into pregnant 
women, and is easily identified with the Kleihauer technique. It is 
understandable that this is the first disease of an immune nature 
for which a specific method of prevention has been developed. 
Several questions about this method still need to be resolved. 
There is some evidence that maternal isoimmunization usually begins 
during pregnancy. However, passive antibody given after delivery still 
effectively suppresses maternal antibody production. Animal studies 
have shown that the immune response can be suppressed as long as 40 
days after antigen is introduced. It is possible, then, that some of 
the treated mothers who have no antibody six months after delivery 
actually were immunized during pregnancy and then suppressed by passive 
gamma-globulin at delivery. There is a marked difference in the sen-
sitivity of the serologic tests used in the clinical series and small 
-
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amounts of maternal anti-Rho antibody may be overlooked. If this is 
true, these women would be capable of an amnestic immune response 
during a subsequent Rho positive pregnancy. This problem will be 
resoxved when more women have been followed through several Rho pos-
itive pregnancies. It may be necessary to give gamma-globulin during 
pregnancy as Zipursky suggests. 
Another interesting question is raised by this line of thought. 
Theoretically, the maternal immune response could be suppressed by 
very large doses of IgM passive antibody. This antibody does not 
cross the placenta and could do no damage to the fetus. Perhaps 
erythroblastosis fetalis could be prevented even when the mother is 
already immunized by giving I~~ early in pregnancy. 
There are other possibilities. If antibody could be altered 
so that it would still compete with the lymphoid cells for antigen 
but could not produce the changes seen in auto-immune diseases, passive 
antibody could be used to treat these disorders. Perhaps small doses 
of wlaltered, very high affinity antibody could accomplish this. 
Whatever the future applications of these principles, it 
seems likely that hemolytic disease of the newborn caused by the 
Rho antigen will soon go the way of smallpox, diphtheria, and polio. 
pummar,;y: 
In the past 30 years Rho hemolytic disease of the newborn has 
been recognized, its cause found, and its prevention developed. This 
disease occurs in about 0.6% of all deliveries and has a stillbirth 
rate of about 15%, resulting in 5,000 stillbirths each year in the 
____________________________ a ____________________________ _ 
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United States. 
The leakage of fetal red cells across the placenta into the 
maternal circulation is the first event in Rho hemolytic disease, 
Many factors influence this transplacental hemorrhage; but in general, 
TPH is very common during pregnancy, occurs during delivery in about 
one-half of all patients, and is greater than 0.25 mI. in about 10%. 
The mother then produces antibodies to the Rho antigen on the 
fetal red cells. The rate at which maternal isoimmunization occurs 
depends on the dose of fetal cells, the ABO types of the mother and 
fetus, and the variable individual response of the mother. It is not 
clear whether immunization usually occurs during pregnancy or after 
delivery. 
In affected pregnancies the anti-Rho IgG antibodies eross the 
placenta and destroy fetal red cells. There have been attempts to 
interrupt this process at several points. The most successful method 
is suppression of the maternal immune response with passively admin-
istered anti-Rho gamma-globulin. According to the instructional 
theory of antibody production, the passive antibody competes with the 
lymphoid cells and macrophages for antigen. As expected, high affinity 
antibody is more effective than low-affinity antibody and the antigen-
antibody ratio is critical in immune suppression. The phenomenon of 
enhancement of the immune response with small doses of passive gamma-
globulin can also be explained with the present theories. 
Passive anti-Rho gamma-globulin is a safe and very effective method 
of preventing Rh-hemolytic disease of the newborn. There is still some 
-24-
question about the optimal time of administration and whether the 
treatment is still effective after several Rh-positive pregnancies. 
Continued clinical trials will soon answer both questions. The prin-
ciples discovered during the development of this treatment may be 
applicable to other immune diseases. 
--
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